Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 10Lymphoma 10Lymphoma, Follicular 7Recurrence 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, Mantle-Cell 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Mycosis Fungoides 1Mesothelioma 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 8Vincristine 6romidepsin 5Prednisone 5Doxorubicin 5Lenalidomide 4Etoposide 4fludarabine phosphate 3fludarabine 3Rituximab 3Dexamethasone 3Bortezomib 3Azacitidine 3selinexor 2darinaparsin 2carfilzomib 2belinostat 2Oxaliplatin 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Injections 2Gemcitabine 2Depsipeptides 2Dasatinib 2Carboplatin 2Brentuximab Vedotin 2Biopsy 2Bendamustine Hydrochloride 2Alemtuzumab 2umbralisib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Peripheral × obinutuzumab × Clear all
NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

Aptevo Therapeutics

Phase 1 Terminated
87 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡